Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 5/20 | 0.42 |
| ▸ | PRKACA | P17612 | 4/20 | 0.41 |
| ▸ | PRKACG | P22612 | 4/20 | 0.41 |
| ▸ | PRKACB | P22694 | 4/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2051879 | 0.98 | BCL2 (0.43) | BCL2MCL1SRCPRKACAPRKACG | |
| SCHEMBL1805702 | 0.81 | QPCT (0.39) | BCL2MCL1SRCALDH1A1HPGD | |
| SCHEMBL4371995 | 0.80 | CYP3A4 (0.40) | BCL2MCL1GPR35PARP1LMNA | |
| SCHEMBL1663176 | 0.77 | LMNA (0.51) | PARP1LMNAMEN1KMT2APOLB | |
| SCHEMBL2574527 | 0.77 | LMNA (0.57) | PARP1LMNAMEN1KMT2APOLB | |
| SCHEMBL3429702 | 0.76 | MAPT (0.43) | BCL2MCL1PARP1MEN1KMT2A | |
| SCHEMBL8934855 | 0.76 | MAPT (0.53) | PARP1MEN1KMT2APNPALDH1A1 | |
| SCHEMBL22962863 | 0.76 | PARP1 (0.41) | PARP1MEN1KMT2APNPALDH1A1 | |
| SCHEMBL30882780 | 0.73 | PDE3B (0.44) | PARP1LMNAMEN1KMT2APOLB | |
| SCHEMBL29258736 | 0.73 | PDE3B (0.44) | PARP1LMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
| EP-1994021-A2 | QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007103370-A2 | QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | BCL2 3798/4885MCL1 252/4885SRC 308/4885 |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | BCL2 3295/4885MCL1 2347/4885SRC 4187/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | BCL2 3973/4885MCL1 2445/4885SRC 4115/4885 |
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE5A, PDE7A | BCL2 4005/4885MCL1 2291/4885SRC 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.